4D Molecular grants CEO 750K stock options

4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock.

Rhea-AI Filing Summary

4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock. The option has an exercise price of $9.88 per share and expires on March 24, 2036.

The award vests over four years, with 1/48 of the shares vesting monthly starting on March 25, 2026, so long as he continues as a service provider. Following this grant, the filing shows 750,000 derivative securities (options) held directly by Kirn.

Insights

Equity Compensation Analyst

Large CEO option grant aligns incentives but is routine compensation.

The company granted CEO David Kirn options for 750,000 shares at an exercise price of $9.88, expiring in 2036. This is compensation, not a market purchase, so it does not signal his short-term view on the stock.

The options vest in equal monthly installments over four years starting March 25, 2026, contingent on continued service. This structure encourages long-term retention and performance but the filing does not quantify his total equity stake, so the overall dilution and ownership impact cannot be fully assessed from this data alone.

Insider Trade Summary

Grant/Award: 750,000 shares

Grant/Award 1 txn

Insider Kirn David

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	750,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 750,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FDMT CEO David Kirn receive in this Form 4 filing?

David Kirn received a stock option grant for 750,000 shares of 4D Molecular Therapeutics common stock at an exercise price of $9.88 per share. The option is compensation, not an open-market share purchase, and appears as a derivative security in the filing.

How do the FDMT CEO stock options vest under this grant?

The options vest over four years, with 1/48 of the 750,000 underlying shares vesting on each monthly anniversary of March 25, 2026. Full vesting occurs on the fourth anniversary, provided David Kirn continues as a service provider to 4D Molecular Therapeutics throughout that period.

When do David Kirn’s newly granted FDMT options expire?

The stock options granted to David Kirn expire on March 24, 2036, giving a 10-year term from the grant date. After that expiration date, any unexercised options become worthless and cannot be used to purchase 4D Molecular Therapeutics common shares.

Is the FDMT CEO’s Form 4 transaction a stock purchase or a grant?

The Form 4 reflects a grant of stock options, not an open-market stock purchase. The transaction is coded as an award (code A), meaning David Kirn acquired derivative securities as compensation, exercisable at $9.88 per share for 750,000 underlying common shares.

How many FDMT derivative securities does David Kirn hold after this grant?

After the grant, the filing shows David Kirn holding 750,000 derivative securities, all from this stock option award. These options give him the right to buy an equal number of 4D Molecular Therapeutics common shares at the specified exercise price before the expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.88	03/25/2026		A		750,000		(1)	03/24/2036	Common Stock	750,000	$0	750,000	D

Explanation of Responses:

1. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)